Pre-transplantation testing: who, when and why?

Farrington, M; Tedder, R; Kibbler, C; Wreghitt, T; Gould, K; Tremlett, CH

doi:10.1016/S0195-6701(99)90094-4

Pre-transplantation testing: who, when and why?

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

An ever-widening range of human organs and tissues is being transplanted, limited currently only by the ingenuity of surgeons and immunologists to overcome the physical and immune barriers, Microbiologists are in danger of being left behind. Although the major infective risks of human organ transplantation are now well understood, many details remain controversial, and the special risks associated with tissue banking have received little attention until recently. What should we do? Are we making mountains out of molehills? Are there any data on which to base a rational decision? Topics covered include: bacteriology of cadaveric heart valve transplantation (why are valves not cultured and only dunked in antibiotic solution for 24 h, whereas endocarditis gets treated for 3 weeks?); screening for tissue-born viruses (why does everyone persist with serology when genomic methods are so much better?), screening organ donors for CMV (surely we should use the optimally; sensitive combination of methods?); peripheral blood stem cell transplants (should we culture these, and what do the positive results mean if we do?); donor sputum screening before heart-lung transplantation (does this aid the post-operative management of the recipient?). With active participation from the floor some areas of consensus were identified and topics worthy of scientific investigation in the future were highlighted. (C) 1999 Hospital Infection Society.